19-28z CAR T cells: Additional Phase I data

An open-label, U.S. Phase I trial in patients with relapsed or refractory B cell ALL showed that JCAR015 led to 23 complete

Read the full 220 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE